CY1121566T1 - Νευροπροστατευτικο και ενδειξη αυτου - Google Patents
Νευροπροστατευτικο και ενδειξη αυτουInfo
- Publication number
- CY1121566T1 CY1121566T1 CY20191100322T CY191100322T CY1121566T1 CY 1121566 T1 CY1121566 T1 CY 1121566T1 CY 20191100322 T CY20191100322 T CY 20191100322T CY 191100322 T CY191100322 T CY 191100322T CY 1121566 T1 CY1121566 T1 CY 1121566T1
- Authority
- CY
- Cyprus
- Prior art keywords
- neuroprotective
- indication
- androstane
- triol
- hypoxia
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title 1
- IFRIPYPBJCUNAG-OTMXHXQLSA-N (3s,5r,6r,8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5,6-triol Chemical compound C([C@]1(O)[C@H](O)C2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 IFRIPYPBJCUNAG-OTMXHXQLSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000008445 altitude sickness Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Eye Examination Apparatus (AREA)
Abstract
Παρέχεται η χρήση της 5α-ανδροσταν-3β,5,6β-τριόλης και αναλόγων αυτής στην παρασκευή ενός φαρμάκου για τη θεραπεία ή την πρόληψη νόσου του υψόμετρο επαγόμενης από υποβαρική υποξία.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410170263.7A CN105012313B (zh) | 2014-04-25 | 2014-04-25 | 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用 |
| PCT/CN2015/076528 WO2015161747A1 (zh) | 2014-04-25 | 2015-04-14 | 神经保护剂及其适应症 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121566T1 true CY1121566T1 (el) | 2020-05-29 |
Family
ID=54331734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100322T CY1121566T1 (el) | 2014-04-25 | 2019-03-18 | Νευροπροστατευτικο και ενδειξη αυτου |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10357500B2 (el) |
| EP (1) | EP3135288B1 (el) |
| JP (1) | JP6277289B2 (el) |
| KR (1) | KR101873791B1 (el) |
| CN (2) | CN108125965B (el) |
| AU (1) | AU2015251359B2 (el) |
| CA (1) | CA2946647C (el) |
| CY (1) | CY1121566T1 (el) |
| DK (1) | DK3135288T3 (el) |
| ES (1) | ES2711842T3 (el) |
| HR (1) | HRP20190806T1 (el) |
| HU (1) | HUE043685T2 (el) |
| IL (1) | IL248424B (el) |
| LT (1) | LT3135288T (el) |
| PL (1) | PL3135288T3 (el) |
| PT (1) | PT3135288T (el) |
| RS (1) | RS58476B1 (el) |
| RU (1) | RU2672264C2 (el) |
| SG (1) | SG11201608829SA (el) |
| SI (1) | SI3135288T1 (el) |
| TR (1) | TR201901516T4 (el) |
| WO (1) | WO2015161747A1 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3063524A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
| CN109985049B (zh) * | 2017-12-29 | 2022-02-22 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用 |
| USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
| USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
| USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
| CN113318114B (zh) * | 2020-02-28 | 2023-02-17 | 广州市赛普特医药科技股份有限公司 | 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1090795A (en) * | 1993-11-12 | 1995-05-29 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
| CN101164540A (zh) * | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| JP5542064B2 (ja) * | 2008-01-22 | 2014-07-09 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 |
| US7906159B2 (en) * | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| CN101683348B (zh) * | 2008-09-23 | 2012-07-04 | 中山大学 | 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用 |
| CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
| CN102180928B (zh) * | 2011-03-15 | 2013-01-16 | 广州市赛普特医药科技有限公司 | 3β,5α,6β-三羟基甾体化合物及其合成方法和应用 |
| RU2461376C1 (ru) * | 2011-05-25 | 2012-09-20 | Государственное образовательное учреждение высшего профессионального образования "Смоленская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации | Антигипоксантное средство |
-
2014
- 2014-04-25 CN CN201711306184.4A patent/CN108125965B/zh active Active
- 2014-04-25 CN CN201410170263.7A patent/CN105012313B/zh active Active
-
2015
- 2015-04-14 CA CA2946647A patent/CA2946647C/en active Active
- 2015-04-14 SI SI201530624T patent/SI3135288T1/sl unknown
- 2015-04-14 EP EP15783742.8A patent/EP3135288B1/en active Active
- 2015-04-14 KR KR1020167032304A patent/KR101873791B1/ko active IP Right Grant
- 2015-04-14 PT PT15783742T patent/PT3135288T/pt unknown
- 2015-04-14 DK DK15783742.8T patent/DK3135288T3/en active
- 2015-04-14 RU RU2016141462A patent/RU2672264C2/ru active
- 2015-04-14 US US15/306,437 patent/US10357500B2/en active Active
- 2015-04-14 SG SG11201608829SA patent/SG11201608829SA/en unknown
- 2015-04-14 AU AU2015251359A patent/AU2015251359B2/en active Active
- 2015-04-14 ES ES15783742T patent/ES2711842T3/es active Active
- 2015-04-14 WO PCT/CN2015/076528 patent/WO2015161747A1/zh active Application Filing
- 2015-04-14 RS RS20190348A patent/RS58476B1/sr unknown
- 2015-04-14 PL PL15783742T patent/PL3135288T3/pl unknown
- 2015-04-14 LT LTEP15783742.8T patent/LT3135288T/lt unknown
- 2015-04-14 JP JP2016563798A patent/JP6277289B2/ja active Active
- 2015-04-14 TR TR2019/01516T patent/TR201901516T4/tr unknown
- 2015-04-14 HU HUE15783742A patent/HUE043685T2/hu unknown
-
2016
- 2016-10-20 IL IL248424A patent/IL248424B/en active IP Right Grant
-
2019
- 2019-03-18 CY CY20191100322T patent/CY1121566T1/el unknown
- 2019-04-30 HR HRP20190806TT patent/HRP20190806T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| CY1122602T1 (el) | Αντιμετωπιση των nafld και nash | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CY1120950T1 (el) | Θεραπεια ινωσης | |
| CL2016002971A1 (es) | Combinación. | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| CY1122971T1 (el) | Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| MX2022000746A (es) | Dimetilfumarato y regimenes de vacunacion. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| FI20165467A (fi) | Menetelmä käyttäjän lääkityksen hallinnoimiseksi | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| WO2016082807A3 (zh) | 伊曲康唑的新用途 | |
| BR112017009577A2 (pt) | análogos de pantotenamida | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| MX2016013979A (es) | Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina. | |
| UA37478S (uk) | Шприц медичний | |
| UA98822U (en) | APPLICATION OF KAPIKOR (MELDONIUM DIHYDRATE AND γ-BUTYROBETAINE DIHYDRATE) MEDICINE AS THE ENDOTHELIUM PROTECTOR WITH ANTI-ISCHEMIC EFFECT | |
| IN2014DE00822A (el) |